Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GLTO 
Galecto Inc (GLTO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: GLTO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -82.78% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.55M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 2 | Beta 1.35 | 52 Weeks Range 2.01 - 15.12 | Updated Date 08/15/2025 |
52 Weeks Range 2.01 - 15.12 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.07 |
Earnings Date
Report Date 2025-08-05 | When - | Estimate - | Actual -2.6 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.33% | Return on Equity (TTM) -96.08% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -4247521 | Price to Sales(TTM) - |
Enterprise Value -4247521 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.46 | Shares Outstanding 1324560 | Shares Floating 1216781 |
Shares Outstanding 1324560 | Shares Floating 1216781 | ||
Percent Insiders 3.68 | Percent Institutions 12.91 |
Upturn AI SWOT
Galecto Inc
Company Overview
History and Background
Galecto, Inc. is a biotechnology company focused on developing novel treatments for fibrosis and cancer. Founded in 2011, Galecto has focused on developing galectin modulators.
Core Business Areas
- Fibrosis Drug Development: Developing and commercializing galectin-3 inhibitors for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH).
- Cancer Drug Development: Researching and developing galectin-3 inhibitors for cancer treatment. The company has a pipeline focused on cancer immunotherapy.
Leadership and Structure
The company is led by Hans Schambye (CEO). The organizational structure is based on functional departments such as research and development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- GB0139: An inhaled formulation of a galectin-3 inhibitor being developed for IPF. Currently in clinical trials. There is currently no market share data, and competitors include Boehringer Ingelheim (Ofev) and Roche (Esbriet).
- GB1211: An oral formulation of a galectin-3 inhibitor being developed for NASH and other indications. Currently in clinical trials. There is currently no market share data, and competitors include Madrigal Pharmaceuticals.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with significant investment in research and development. The market for fibrosis and cancer therapeutics is large and growing due to an aging population and increasing prevalence of these diseases.
Positioning
Galecto is positioned as an innovator in the field of galectin-3 inhibition. Its competitive advantage lies in its proprietary technology platform and pipeline of novel galectin-3 inhibitors.
Total Addressable Market (TAM)
The total addressable market for IPF and NASH is estimated to be in the billions of dollars. Galecto is positioned to capture a significant share of this market if its clinical trials are successful.
Upturn SWOT Analysis
Strengths
- Novel technology platform
- Strong intellectual property portfolio
- Experienced management team
- Promising clinical trial results
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Small market capitalization
- Limited commercialization experience
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Regulatory approval for lead product candidates
- Growing market for fibrosis and cancer therapeutics
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- BI
- RHHBY
- GTHX
Competitive Landscape
Galecto is a smaller company compared to its competitors, but it has a novel technology platform. It has the disadvantage of not having any revenues, and only drugs in clinical trials. Advantage is if the trials are successful it can become a market leader.
Growth Trajectory and Initiatives
Historical Growth: Historically growth has been based on funding rounds and clinical milestones
Future Projections: Future growth is based on successful clinical trials and FDA approval, as well as successful acquisition deals.
Recent Initiatives: Focusing on its lead galectin-3 inhibitor programs, GB0139 and GB1211.
Summary
Galecto is a biotechnology company focused on developing novel treatments for fibrosis and cancer. The company's strength lies in its novel technology platform and promising clinical trial results. However, the company faces challenges due to its limited financial resources and dependence on clinical trial success. Future growth depends on partnerships and regulatory approvals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on available data and subject to change. Investing in biotechnology companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galecto Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-10-29 | Co-Founder, President, CEO & Director Dr. Hans T. Schambye M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://galecto.com |
Full time employees 5 | Website https://galecto.com | ||
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.